` MYGN (Myriad Genetics Inc) vs S&P 500 Comparison - Alpha Spread

MYGN
vs
S&P 500

Over the past 12 months, MYGN has underperformed S&P 500, delivering a return of -79% compared to the S&P 500's 9% growth.

Stocks Performance
MYGN vs S&P 500

Loading
MYGN
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
MYGN vs S&P 500

Loading
MYGN
S&P 500
Difference
www.alphaspread.com

Performance By Year
MYGN vs S&P 500

Loading
MYGN
S&P 500
Add Stock

Competitors Performance
Myriad Genetics Inc vs Peers

S&P 500
MYGN
ABBV
AMGN
GILD
VRTX
Add Stock

Myriad Genetics Inc
Glance View

Market Cap
462.9m USD
Industry
Biotechnology

Nestled at the crossroads of healthcare innovation and genetic science, Myriad Genetics Inc. has been a pioneering force in molecular diagnostics for over three decades. Founded in 1991 and headquartered in Salt Lake City, Utah, the company carved out its niche by focusing on predictive medicine—an area that seeks to forecast disease risk based on genetic predispositions. At the heart of Myriad's operations is its robust arsenal of genetic tests that identify individuals' risk for various conditions, including cancer, cardiovascular illnesses, and other hereditary disorders. This approach not only aids early intervention and personalized treatment plans but also empowers patients with crucial information about their genetic backgrounds. Myriad's business model orbits around the research, development, and commercialization of these high-impact diagnostic tests. Revenue streams flow primarily from the sale of its flagship products, which include the BRACAnalysis CDx test for assessing breast and ovarian cancer risk and various other hereditary cancer tests that evaluate susceptibility to prostate and colorectal cancers. Further, Myriad advances its impact through collaborations with healthcare providers, folding clinical research findings into broader medical practice. In a world where healthcare is increasingly leaning towards precision medicine, Myriad Genetics stands as a testament to the value of science-led business strategies, sustaining its growth through a clear focus on marrying advanced genomic knowledge with accessible and actionable clinical applications.

MYGN Intrinsic Value
18.93 USD
Undervaluation 73%
Intrinsic Value
Price
Back to Top